Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients.
The FDA will next determine whether pSivida’s NDA is complete and acceptable for review.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
From around 2014 through 2016, Valeant seemingly had a crisis story per week, ranging from insider trading to channel stuffing
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.
The agency inspected the plant from May 15 to May 24, 2017, and observed that staffers at the plant were basically gaming the quality control system.
Evan Greebel was found guilty by a federal jury in Brooklyn of charges he conspired to commit wire fraud and securities fraud.
The U.S. Food and Drug Administration on Friday said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.
For the first time in years, the medical device tax will take effect Jan. 1, after Congress left town without delivering on a long-promised delay or repeal.